Peptide LibrarySermorelin dosage in published studies and labels
These are the doses used for Sermorelin in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
Sermorelin has published human dosing from pharmacology studies of GHRH(1-29)-NH2: 0.25 mcg/kg intravenously already produces significant growth hormone release, with a maximal response at 1–2 mcg/kg, and roughly 50 mcg/kg intranasally is about as potent as 1 mcg/kg intravenously. That dosing is weight-based and acute. DailyMed lists no current FDA-labelled sermorelin product.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 0.25–2 mcg/kg intravenously (about 50 mcg/kg intranasally) |
| Route | Intravenous · Intranasal · Subcutaneous |
| Frequency | Single administration in the published dose-response work |
| Duration studied | Acute pharmacology protocols |
| Evidence level | Limited Human Evidence |
| Last reviewed | 2026-09-05 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| GHRH(1-29)-NH2 pharmacokinetics and dose-responseClinical trial · Human dose-response pharmacology study | Human subjects in a dose-response protocol | 0.25 mcg/kg produced significant GH release; maximal response at 1–2 mcg/kg intravenously; ~50 mcg/kg intranasally equivalent to 1 mcg/kg intravenously | Intravenous and intranasal | Single dose per level | Acute | Growth hormone release and pharmacokinetics | Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion. Acta Paediatr Suppl. 1993. |
| Growth hormone deficiency treatment study (1987)Clinical trial · Clinical study | Patients with growth hormone deficiency | Per study protocol | Subcutaneous | — | — | Growth response in GH deficiency | Treatment of growth-hormone deficiency with growth-hormone-releasing hormone. Lancet. 1987. |
| NCT01060488 — GHRH diagnostic validationClinical trial · Phase 3 diagnostic validation trial | Adults undergoing growth hormone testing (n=69) | Per trial protocol | Intravenous | — | — | Validation of the GHRH-arginine stimulation test | NCT01060488 — Comparative Validation of the Growth Hormone Releasing Hormone and Arginine Test |
Where sources disagree
- Published dosing is weight-based and micrograms per kilogram — roughly 17–140 mcg for a 70 kg adult intravenously. Sermorelin is sold with fixed protocols commonly quoted at 200–500 mcg subcutaneously nightly, which is well above the studied intravenous range and by a different route.
- DailyMed lists no current FDA-labelled sermorelin product, so there is no active prescribing information to cite for a maintenance regimen. The published human evidence is acute pharmacology and diagnostic testing, not long-term treatment.
- Most registered trials returned when searching sermorelin actually studied other GHRH analogues, chiefly tesamorelin (TH9507). Evidence for tesamorelin is not dosing evidence for sermorelin.